Vector and cell engineering to increase productivity and stability of recombinant protein production in CHO cells

载体和细胞工程可提高 CHO 细胞中重组蛋白生产的生产力和稳定性

• 批准号: 298293-2011
• 负责人: Massie, Bernard
• 金额: $ 2.91万
• 依托单位: Université de Montréal
• 依托单位国家: 加拿大
• 项目类别: Discovery Grants Program - Individual
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=525957
• 关键词: Vector; cell; engineering; increase; productivity

Biologics (proteins, antibodies and vaccines) account for a significant (7.5%) and increasing share (20% annual growth) of new therapeutics entering the clinic and the market, displacing the traditional small-molecule chemical compounds; 33% of all drugs currently in development are biologics (PharmaVision 2009. Delivering New Biopharmaceutical Therapies: Challenges & Opportunities). Together with vaccines and gene therapy products, therapeutic proteins represent half of the FDA-approved therapeutics in the pipeline. As a result, we are witnessing a spectacular emergence of biologics in the top 10 most selling drugs. In 2000, there was only one biologic in the top 10: erythropoietin. The forecast for 2014 indicated that there would be 7 biologics in the top 10: 5 humanized antibodies and 2 recombinant proteins (Biotech 2010 Live Sciences: Adapting for success, Burrill & Company). Hence, therapeutic antibodies and derivatives thereof have the lion's share of this market. In order to expand their applications, significant improvements are required to lower their production costs while improving their quality. Thus, it is estimated that the cost of production of therapeutic antibodies must be reduced by at least one order of magnitude in order to ensure economic viability of a significant proportion of the products currently in clinical trials. Therefore much remains to be done to improve the efficiency of high-producing clones generation and we will explore new vector and cell engineering strategies toward that goal.

生物制剂（蛋白质、抗体和疫苗）在进入临床和市场的新疗法中占显著（7.5%）和不断增长（年增长率为20%）的份额，取代了传统的小分子化合物;目前正在开发的所有药物中有33%是生物制剂（PharmaVision 2009.提供新的生物制药疗法：挑战与机遇）。与疫苗和基因治疗产品一起，治疗性蛋白质占FDA批准的治疗药物的一半。因此，我们正在目睹生物制剂在十大最畅销药物中的惊人崛起。在2000年，只有一种生物制剂进入前10名：促红细胞生成素。2014年的预测表明，前10名中将有7种生物制剂：5种人源化抗体和2种重组蛋白（Biotech 2010 Live Sciences：Adapting for success，Burrill & Company）。因此，治疗性抗体及其衍生物在该市场中占有最大份额。为了扩大其应用，需要进行重大改进，以降低其生产成本，同时提高其质量。因此，据估计，治疗性抗体的生产成本必须降低至少一个数量级，以确保目前在临床试验中的大部分产品的经济可行性。因此，仍有许多工作要做，以提高效率的高产克隆一代，我们将探索新的载体和细胞工程策略，实现这一目标。